Curis to Release Second Quarter 2023 Financial Results and Hold Conference Call on August 3, 2023

Rhea-AI Summary

Curis, Inc. (NASDAQ: CRIS) announced the release of its second quarter 2023 financial results on August 3, 2023. A conference call will be hosted by the management at 4:30 p.m. ET on the same day.

Positive

• Curis, Inc. will release its second quarter 2023 financial results, which could provide positive insights for investors.

Negative

• None.

LEXINGTON, Mass., July 27, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor for the treatment of hematologic malignancies, today announced that the Company will release its second quarter 2023 financial results on Thursday, August 3, 2023, after the close of U.S. markets. Management will host a conference call on the same day at 4:30 p.m. ET.

To access the live conference call, please dial (888)-346-6389 from the United States or (412)-317-5252 from other locations, shortly before 4:30 p.m. ET. The conference call can also be accessed on the Curis website at www.curis.com in the 'Investors' section. A replay of the financial results conference call will be available on the Curis website shortly after completion of the call.

About Curis, Inc.

Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor for the treatment of hematologic malignancies. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, emavusertib (CA-4948). Emavusertib is currently undergoing testing in the Phase 1/2 TakeAim Lymphoma study in patients with hematologic malignancies, such as non-Hodgkin's lymphoma and other B cell malignancies both as a monotherapy and in combination with the BTK inhibitor ibrutinib, and the Phase 1/2 TakeAim Leukemia study in patients with acute myeloid leukemia and myelodysplastic syndrome, for which it has received Orphan Drug Designation from the U.S. Food and Drug Administration. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-to-release-second-quarter-2023-financial-results-and-hold-conference-call-on-august-3-2023-301887903.html

SOURCE Curis, Inc.

FAQ

When will Curis, Inc. release its second quarter 2023 financial results?

Curis, Inc. will release its second quarter 2023 financial results on August 3, 2023.

What time will the conference call be held?

The conference call will be held at 4:30 p.m. ET on August 3, 2023.

Where can I access the live conference call?

The live conference call can be accessed by dialing (888)-346-6389 from the United States or (412)-317-5252 from other locations. It can also be accessed on the Curis website at www.curis.com in the 'Investors' section.

Will there be a replay of the financial results conference call?

Yes, a replay of the financial results conference call will be available on the Curis website shortly after completion of the call.